Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relmada to Discontinue Reliance II and Relight Phase 3 Studies of REL-1017
Details : REL-1017 (esmethadone) NMDA receptor inhibitor, small molecule drug candidate, which is being evaluated as an adjunct treatment for the treatment of major depressive disorder.
Product Name : REL-1017
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relmada Finds Phase 3 Reliance II Trial Futile At Interim Analysis
Details : REL-1017 is a NCE and novel NMDAR channel blocker that targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, in major depressive disorder patients.
Product Name : REL-1017
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 04, 2024
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the study, the REL-1017 treatment arm showed a MADRS reduction of 14.8 points at Day 28 versus 13.9 points for the placebo arm, a higher than expected placebo response.
Product Name : REL-1017
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2022
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REL-1017, a new chemical entity and novel NMDA receptor channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of major de...
Product Name : REL-1017
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 12, 2022
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REL-1017 (esmethadone), new chemical entity and novel NMDA receptor channel blocker preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, in late-stage development for treatment of major depressive d...
Product Name : REL-1017
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 25, 2022
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology
Details : REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatme...
Product Name : REL-1017
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 29, 2022
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatme...
Product Name : REL-1017
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 04, 2022
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Relmada Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
Details : Top-line results showed that all three doses of REL-1017 (25 mg, 75 mg and 150 mg) tested in recreational opioid users, demonstrated a highly statistically significant difference vs. the active control drug, oxycodone 40 mg.
Product Name : REL-1017
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2021
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Arbormentis
Deal Size : $165.0 million
Deal Type : Acquisition
Relmada Therapeutics Announces the Acquisition of Novel Psilocybin and Derivates
Details : Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
Product Name : REL-1017
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
July 20, 2021
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Arbormentis
Deal Size : $165.0 million
Deal Type : Acquisition
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development as an adjunctive treatment for MDD in adults.
Product Name : REL-1017
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2021
Lead Product(s) : Esmethadone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable